
ImmuCell Corporation ICCC
$ 6.57
3.46%
Quarterly report 2025-Q3
added 11-13-2025
ImmuCell Corporation DPO Ratio 2011-2026 | ICCC
Annual DPO Ratio ImmuCell Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.92 | 4.03 | 13.8 | 22.9 | 58.1 | 29.9 | 38 | 85.6 | 133 | 18.4 | 52.9 | 18.8 | 35.7 | 23.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 133 | 4.03 | 38.6 |
Quarterly DPO Ratio ImmuCell Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5.41 | 5.11 | 3.91 | - | 10.7 | 28.1 | 12.1 | - | 20 | 25.6 | 20.8 | - | 18.7 | 20.8 | 23.1 | - | 27.5 | 32.7 | 17.1 | - | 24.1 | 25.1 | 19.3 | - | 40.3 | 31.7 | 33.3 | - | 49.5 | 64 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 64 | 3.91 | 24.3 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
ADMA Biologics
ADMA
|
35.9 | $ 15.36 | -2.17 % | $ 3.66 B | ||
|
Cellectis S.A.
CLLS
|
975 | $ 3.53 | -3.54 % | $ 116 M | ||
|
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
2.41 K | - | -19.68 % | $ 18.4 M | ||
|
Aptorum Group Limited
APM
|
405 | $ 0.79 | -1.15 % | $ 4.31 M | ||
|
China SXT Pharmaceuticals
SXTC
|
324 | $ 2.01 | -1.36 % | $ 2.86 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Anika Therapeutics
ANIK
|
54.4 | $ 14.05 | -1.44 % | $ 206 M | ||
|
ANI Pharmaceuticals
ANIP
|
60.1 | $ 74.36 | -1.64 % | $ 1.44 B | ||
|
AVEO Pharmaceuticals
AVEO
|
235 | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
529 | $ 162.43 | 0.6 % | $ 8.08 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
484 | $ 8.49 | -0.18 % | $ 1.75 B | ||
|
BridgeBio Pharma
BBIO
|
399 | $ 65.66 | -0.78 % | $ 12.6 B | ||
|
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | ||
|
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
BioMarin Pharmaceutical
BMRN
|
245 | $ 61.3 | 1.21 % | $ 11.8 B |